Gilbert's syndrome and antiviral therapy of hepatitis C

Annals of Hepatology

Volumn 8, Issue 3, 2009, Pages 246-250

  Deterding, Katja ^a   Grungreiff, Kurt ^b   Lankisch, Tim O ^a   Potthoff, Andrej ^a   Bahr, Matthias J ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Medical practice for Gastroenterology

Author keywords

Antiviral therapy; Gilbert's syndrome; Hepatitis C

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CASE REPORT; DNA SEQUENCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FEVER; FLU LIKE SYNDROME; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; HEPATITIS C; HOMOZYGOSITY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LEUKOPENIA; LIVER FUNCTION; MALE; PROMOTER REGION; PRURITUS; SEQUENCE ANALYSIS; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; VIREMIA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; GENETICS; MIDDLE AGED;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GILBERT DISEASE; HEPATITIS C, CHRONIC; HUMANS; HYPERBILIRUBINEMIA; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; YOUNG ADULT;

EID: 77952525323     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31774-0     Document Type: Article

References (27)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff-man M, Reindollar R, Goodman ZD, Koury K, Ling M, Albre-cht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
2. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002; 4: 23-30.
3. Manns MP, Wedemeyer H. Handbuch Hepatitis C: Diagnos-tik, Verlauf, Therapie. Unimed Verlag 2003.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginter-feron-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
5. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.
6. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9: S90-S94.
7. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
8. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31(Suppl. 1): 193-196.
9. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003; 38: 543-544.
10. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32: 91-96.
11. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-477.
12. Strassburg C.P. Pharmacogenetics of Gilbert's syndrome. 2008. Ref Type: Generic.
13. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elfe-rink RP. The genetic basis of the reduced expression of bi-lirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
14. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyl transferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-581.
15. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266: 1043-1047.
16. Strassburg CP, Lankisch TO, Manns MP, Ehmer U. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol 2008.
17. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Ba-rut A, Tukey RH, Manns MP. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransfe-rase activity in human small intestine. J Biol Chem 2000; 275: 36164-36171.
18. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, Jansen PL. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant biliru-bin glucuronidating isoform in man. J Biol Chem 1994; 269: 17960-17964.
19. Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucu-ronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992; 90: 150-155.
20. Arias IM. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest 1962; 41: 2233-2245.
21. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845-847.
22. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, Strassburg CP. Gilbert's Syndrome and irino-tecan toxicity: combination with UDP-glucuronosyltrans-ferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 695-701.
23. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP. Gilbert's disease and ata-zanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44: 1324-1332.
24. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyl-transferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729-1739.
25. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, andros-terone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) probes for human udp-glucuro-nosyltransferases. Drug Metab Dispos 2006; 34: 449-456.
26. Erichsen TJ, Ehmer U, Kalthoff S, Lankisch TO, Muller TM, Munzel PA, Manns MP, Strassburg CP. Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol 2008.
27. Ellis E, Wagner M, Lammert F, Nemeth A, Gumhold J, Stras-sburg CP, Kylander C, Katsika D, Trauner M, Einarsson C, Marschall HU. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J Hepatol 2006; 44: 243-245.